India, Oct. 25 -- A low-cost, platinum-based chemotherapy drug, carboplatin, can now be utilised to increase chances of survival among women with aggressive breast cancer, as per a 10-year-long study and Phase-3 clinical trial conducted by Tata Memorial Centre (TMC).

The total cost of carboplatin for the entire eight-week treatment is estimated to be between Rs.5,000 and Rs.6,000, ranging from Rs.625 to Rs.750 per dose every week. The total cost drugs for the eight-week treatment and chemotherapy comes up to Rs.25,000.

The study, funded by the Department of Atomic Energy, included 720 women with locally advanced stage 3 triple-negative breast cancer (TNBC) and was conducted from 2010 to 2020.

TNBC is an aggressive form of breast cancer...